• Separating Growth Arrest from Cell Death in Drug Response

  2026-08-14

  Hannah Schwartz’s dissertation identifies a central interpretive problem in cancer pharmacology: relative viability and fractional viability are often treated as interchangeable even though they capture different biological outcomes. Its framework shows that drug-induced proliferation arrest and cell death can occur in different proportions and on different timelines, supporting more precise evaluation of anticancer responses in vitro.

• SU 5402: Reliable RTK Assay Design

  2026-08-14

  This scenario-based guide explains how SU 5402 (SKU A3843) can clarify receptor tyrosine kinase biology in viability, proliferation, cell-cycle, and apoptosis experiments. It covers stock preparation, assay controls, mechanistic interpretation, and practical vendor-selection criteria without treating biochemical potency as a universal cellular dose.

• Caspase-4 Colorimetric Assay Kit Workflow

  2026-08-13

  Turn pyroptosis and inflammatory signaling questions into a practical, quantitative workflow with LEVD-pNA cleavage and pNA calibration. This guide shows how to distinguish caspase-4 enzyme activity from broader cell-death phenotypes and how to extend the assay to ER-targeted cancer research.

• 2X HyperFusion High-Fidelity Master Mix Guide

  2026-08-13

  2X HyperFusion High-Fidelity Master Mix combines a fusion proofreading polymerase with optimized buffer and dNTP components for high accuracy DNA amplification. Its reported blunt-end product generation, fragment capability up to 10 kb, and rapid extension guidance make it relevant to cloning PCR applications, while the cited cancer-immunotherapy study provides application context rather than direct validation of this reagent.

• Mitocytosis-Targeted Mitochondrial Therapy

  2026-08-12

  Deng and colleagues show that mitocytosis can blunt mitochondria-targeted antimetastatic therapy in migrasome-rich breast tumors. Their hybrid membrane nanoplatform combines mitochondrial damage with integrin-mediated mitocytosis inhibition, providing a mechanistic strategy to improve treatment response in the 4T1 model.

• Lovastatin Workflows for HMG-CoA Reductase Research

  2026-08-12

  Build more informative Lovastatin experiments by connecting cholesterol-pathway inhibition with proliferation, apoptosis, efferocytosis, and fibroblast remodeling assays. This practical guide combines dose planning, formulation controls, quantitative readouts, and a plant-development reference framework without overstating cross-domain evidence.

• Elbasvir–Grazoprevir for HCV: Evidence and Methods

  2026-08-11

  The 2021 review by Wang, Huang, and Yu synthesizes the pharmacology, pharmacokinetics, clinical efficacy, safety, and resistance profile of the fixed-dose elbasvir–grazoprevir regimen. Its central contribution is showing how complementary NS5A and NS3/4A inhibition supports effective treatment of HCV genotype 1 and 4 infections, including clinically complex populations.

• AAPH: Calibrating Lipid Peroxidation Assays

  2026-08-11

  AAPH enables controlled oxidative stress experiments without pretending that every lipid-peroxidation phenotype is ferroptosis. This guide connects AAPH chemistry with the PRDX6–GPX4 defense pathway and shows how to design interpretable erythrocyte, membrane, and antioxidant assays.

• Neuromedin S (rat): Practical GPCR Assay Guide

  2026-08-10

  Neuromedin S (rat) provides a defined rat peptide agonist for controlled neuromedin U receptor signaling and GPCR/G protein signaling workflows. It is intended for scientific research assays and should not be used for diagnosis, therapy, or clinical in vivo applications.

• Early Life Adversity, Oxytocin, and Innate Defense

  2026-08-09

  Tan and colleagues identify a circuit-level mechanism linking early life adversity to impaired visually evoked innate defensive behavior in mice. Their findings implicate reduced oxytocin receptor signaling in the intermediate and deep superior colliculus and show that receptor knockdown reproduces, whereas intranasal oxytocin ameliorates, the behavioral deficit.

• Amikacin Disulfate: Applied Assay Workflows

  2026-08-08

  Build stronger antibiotic mechanism studies by pairing amikacin’s 30S ribosomal readout with orthogonal protein-binding and activity assays. This workflow shows how to prepare, compare, troubleshoot, and interpret Amikacin disulfate experiments without mistaking structural preservation for preserved protein function.

• (+)-Bicuculline: Practical Protocol Guide

  2026-08-07

  (+)-Bicuculline is a research tool for competitively inhibiting GABAA receptors so investigators can examine inhibitory synaptic transmission and related changes in neuronal signaling. This guide addresses preparation, storage, controls, and interpretation; the compound is for controlled scientific research only and is not intended for diagnostic, clinical, or therapeutic use.

• Inducing Right Ventricular Cardiomyocytes from hPSCs via BMP

  2026-08-07

  Saito et al. present a refined differentiation protocol enabling the targeted generation of right ventricular-like cardiomyocytes from human pluripotent stem cells by modulating BMP signaling during early development. This methodological advance allows for chamber-specific disease modeling and pharmacological research, addressing a major gap in cardiovascular translational studies.

• JSH-23: Precision NF-κB Inhibitor for Inflammation Research

  2026-08-06

  JSH-23 offers targeted inhibition of NF-κB p65 nuclear translocation, enabling researchers to dissect inflammatory pathways with exceptional specificity. This compound stands apart in inflammation research, supporting robust experimental workflows and translational models, especially where selective pro-inflammatory cytokine inhibition is required.

• Catalpol Enhances Neurovascular Repair in Ischemic Stroke Mo

  2026-08-06

  This article analyzes recent evidence that Catalpol, a natural iridoid glycoside, protects the neurovascular unit (NVU) after ischemic stroke by activating VEGF-PI3K/AKT and MEK1/2/ERK1/2 signaling. These findings expand Catalpol's experimental utility, highlighting mechanistic depth and protocol guidance for neuroprotection and translational stroke research.

15395 records 1/1027 page Next 12345 下5页 Last page